Functional HRD by RAD51 identifies BRCA1 VUS associated with loss of gene function and response to DNA-damaging agents

Casartelli, Chiara; Tommasi, Chiara; Lazzarin, Alessandro; Corianò, Matilde; Tornali, C.; Serra, Olga; Gutiérrez-Enríquez, Sara; Llop-Guevara, Alba; Serra, Violeta

dc.contributor	Vall d'Hebron Barcelona Hospital Campus
dc.contributor.author	Casartelli, Chiara
dc.contributor.author	Tommasi, Chiara
dc.contributor.author	Lazzarin, Alessandro
dc.contributor.author	Corianò, Matilde
dc.contributor.author	Tornali, C.
dc.contributor.author	Serra, Olga
dc.contributor.author	Gutiérrez-Enríquez, Sara
dc.contributor.author	Llop-Guevara, Alba
dc.contributor.author	Serra, Violeta
dc.date.accessioned	2024-07-10T12:16:38Z
dc.date.available	2024-07-10T12:16:38Z
dc.date.issued	2024-07-05
dc.identifier.citation	Casartelli C, Tommasi C, Lazzarin A, Corianò M, Tornali C, Serra O, et al. Functional HRD by RAD51 identifies BRCA1 VUS associated with loss of gene function and response to DNA-damaging agents. ESMO Open. 2024 Jul 5;9(7):103629.
dc.identifier.issn	2059-7029
dc.identifier.uri	https://hdl.handle.net/11351/11690
dc.description	Gene function; DNA
dc.language.iso	eng
dc.publisher	Elsevier
dc.relation.ispartofseries	ESMO Open;9(7)
dc.rights	Attribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.uri	http://creativecommons.org/licenses/by-nc-nd/4.0/
dc.source	Scientia
dc.subject	Càncer - Aspectes genètics
dc.subject	Medicaments antineoplàstics - Ús terapèutic
dc.subject	ADN - Dany
dc.subject	Cromosomes humans - Anomalies - Diagnòstic
dc.subject.mesh	Genetic Testing
dc.subject.mesh	DNA Damage
dc.subject.mesh	Neoplasms
dc.subject.mesh	Antineoplastic Agents
dc.title	Functional HRD by RAD51 identifies BRCA1 VUS associated with loss of gene function and response to DNA-damaging agents
dc.type	info:eu-repo/semantics/article
dc.identifier.doi	10.1016/j.esmoop.2024.103629
dc.subject.decs	pruebas genéticas
dc.subject.decs	daño del ADN
dc.subject.decs	neoplasias
dc.subject.decs	antineoplásicos
dc.relation.publishversion	https://doi.org/10.1016/j.esmoop.2024.103629
dc.type.version	info:eu-repo/semantics/publishedVersion
dc.audience	Professionals
dc.contributor.organismes	Institut Català de la Salut
dc.contributor.authoraffiliation	[Casartelli C, Tommasi C, Lazzarin A, Corianò M, Serra O] Department of Medicine and Surgery, University of Parma, Parma, Italy. Medical Oncology Unit, University Hospital of Parma, Parma, Italy. Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC), Parma, Italy. [Tornali C] Department of Medicine and Surgery, University of Parma, Parma, Italy. [Gutiérrez-Enríquez S] Hereditary Cancer Genetics Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Llop-Guevara A, Serra V] Experimental Therapeutics Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain
dc.identifier.pmid	38970842
dc.relation.projectid	info:eu-repo/grantAgreement/ES/PE2017-2020/PI19%2F01303
dc.relation.projectid	info:eu-repo/grantAgreement/ES/PEICTI2021-2023/PI22%2F01200
dc.rights.accessrights	info:eu-repo/semantics/openAccess